Derrick Rossi

Derrick Rossi was a stem cell biologist at Harvard Medical School and the Harvard Stem Cell Institute when he discovered that modified mRNA could reprogram adult cells into induced pluripotent stem cells without the genetic modification risks of viral vectors. This 2010 breakthrough, published in Cell Stem Cell, formed the scientific foundation of Moderna. Rossi had previously trained at Stanford University and the University of Helsinki, and his work built on the foundational mRNA research of Katalin Karikó and Drew Weissman at the University of Pennsylvania. Rossi's decision to pursue commercialization of mRNA technology rather than pure academic research was driven by the realization that the technology could address a vast range of diseases beyond stem cell reprogramming. The founder's contributions to Moderna exemplify the intersection of academic research, venture capital, and entrepreneurial vision that drives biotechnology innovation.

Derrick Rossi served as a co-founder of Moderna and remained involved in the company's early scientific direction before departing to pursue other ventures. His discovery of modified mRNA reprogramming provided the initial intellectual property that attracted Flagship Pioneering's investment. Rossi later founded other biotechnology companies including Convelo Therapeutics, focused on remyelination therapies for multiple sclerosis. His scientific contributions to mRNA technology were recognized when the Karikó-Weissman foundational research, which enabled Rossi's work, was awarded the Nobel Prize in Physiology or Medicine in 2023. Rossi's role in Moderna's founding illustrates how academic breakthroughs can be translated into commercial enterprises when combined with venture capital and entrepreneurial vision. The founder's ongoing involvement with Moderna reflects a commitment to the company's mission of transforming mRNA science into medicines that improve human health.